Sentences with phrase «based drug screening»

UK - based Intelligent Fingerprinting recently announced the availability of its new fingertip - based drug screening...

UK - based Intelligent Fingerprinting recently announced the availability of its new fingertip - based drug screening system to support Coroner services.

We build up bio-matrices with defined chemical composition to mimic their environment under physiological and pathological conditions, to supply nutrition, to provide signaling, to create polarized conditions, and to, ultimately, allow us to perform cell - based drug screening in 3D model organs.

The ideal situation for context - based drug screening, Simon said, is to test compounds on «matched sets,» meaning that a normal cell's response to a drug is compared side - by - side with a cell with one or a few mutations.

Not exact matches

In the last of those years, the reporters discovered, the federal government actually spent more on urine - based drug tests than it did on «the four most recommended cancer screenings combined.»

The results of this screening of active honeys against pathogenic bacteria has supported the registration of honey as a «Drug» with the Therapeutic Good Administration based on its antimicrobial activity.

The researchers constructed a signature for type 2 diabetes based on 50 genes, then used publically available expression datasets to screen 3,852 compounds for drugs that potentially reverse disease.

The scientists combined computer - based screening and cell - based assays to create a method that can significantly accelerate drug discovery and thereby lower development costs.

«This gives us novel and exciting new therapeutic options to pursue based on results from drug screenings of primary tumor samples from patients.»

Using a robotics - based screening approach, researchers screened a library of 1,192 FDA - approved drugs for any that suppressed tumors in the fly and identified several that improved overall survival.

Target - based screening has enabled scientists to discover many useful new drugs, but some wonder whether this basic discovery strategy has already taken all the «low hanging fruit.»

With PhD student Carmen Lorenz at the MDC and the Berlin Institute of Health (BIH), he teamed up with other MDC researchers and scientists from France to come up with a new cell - based system to carry out drug screens.

In the meantime, Takebe and the rest of the team, led by Hideki Taniguchi, also a stem - cell biologist at Yokohama City University — who are collaborating on the project with researchers at Sekisui Medical, a biotechnology firm based in Tokyo — hope that his liver bud could be useful for toxicity testing in drug screening, for which bile ducts are not needed.

Hermen Overkleeft, Professor of Bio-Organic Synthesis at Leiden University, added: «This work reveals the power of activity - based protein profiling: the probe described here at once enables screening for heparanase inhibitors from large compound collections and is a lead compound for drug development in its own right.

In another method, called target - based screening, potential anticancer drugs are identified by looking for compounds that mimic specific mutations that halt proliferation of cancer cells.

Caribou Biosciences, a developer of technology - based solutions for cellular engineering, today announced that it entered into a collaboration agreement with Novartis under which the two companies will utilize Caribou's proprietary CRISPR - Cas9 platform to research new CRISPR - based drug target screening and validation technologies.

Illustrative of this approach, Caribou recently announced a collaboration agreement with Novartis Institutes for Biomedical Research under which the two companies will utilize Caribou's proprietary CRISPR - Cas9 platform to research new CRISPR - based drug target screening and validation technologies.

Caribou is advancing its CRISPR - Cas9 platform in drug target screening and validation to help overcome the limitations of current RNAi - based approaches.

The collaboration is based on expanding Pelago's CETSA technology capabilities and will enable screening of large chemical libraries for identification of novel chemical leads with high drug potential.

Due to the high efficiency of establishing organoid models from different tissues and diseases, such as cancer, organoid technology allows the generation of large living biobanks of tumor organoids that are amenable for middle - throughput drug screens and may allow personalized therapy design, as a complement to cell line and xenograft - based drug studies (7,19).

In the longer term, Revive aims to nucleate an even larger scale effort that will bring together an expanding number leading scientists, clinicians and biotechnology companies into a national Consortium for stem cell - based regenerative medicine and drug screening.

CDI is currently supplying embryonic stem cell - derived heart cells to California - based Roche and other pharmaceutical companies for drug screening, and hopes to create other cell types in the future.

In the search for compounds that might alter a protein's behavior or function — such as that of alpha - synuclein — drug companies often rely on so - called target - based screens that test the effect large numbers of compounds have on the protein in question in rapid, automated fashion.

In the latter area, more than 50 % of drug discovery screens use cell ‑ based assays, predominantly targeting receptors and ion channels using fluorescence ‑ based measurements, in either or both high throughput and high ‑ content formats (1).

Scientists can screen collections of small organic molecules — the type of molecules needed for pill - based drugs — to find any that compete with the peptides by binding tightly to Gα proteins and preventing them from transmitting signals.

Relevant publications: (1) Drug repurposing, computer - based screening (2) Functional testing and novel tools for bioapplications (3) Therapeutic targets and disease pathways by bioinformatic analysis

This latter point will permit a more in - depth analysis of MuSC biology, genetic modification / correction of MuSCs, drug screenings, and, importantly, the development of new and improved MuSC - based therapies for a wide range of muscle diseases.

The human genome's most appealing idea stemmed from the concept of hyper - personalized medicine, in which drugs, vaccines, diagnostic screenings and treatments could be tailored to a specific person based on his or her genetics.

The self - renewable capacity of these cells, their ability to differentiate into several tissue progenitors (neural, mesenchymal stem cells...), and the possibility to work with mutated cell lines define human stem cells as a good basis for screening compounds libraries in order to discover new potential drugs for monogenic diseases.

For example, the goal of the drug response challenge is to predict how a tumor will respond to a drug based on the characteristics of both the tumor and the drug, the information for which is identified through previously available data, such as tumor samples and previous drug screens.

Cellecta Inc., a functional genomics solutions provider, focuses primarily on developing and implementing flexible and scalable broad - based screening and analysis approaches for drug target and biomarker discovery.

These cells also provide a significant advantage for cell - based compound screening in drug discovery.

His previous work at IDRI has included investigations into the physiology of the M.tuberculosis (Mtb) cell wall, the development of an overexpression library for high throughput target identification, and the development of target based high throughput screens for potential drug candidates against Mtb.

Vividion is using fragment - based screening to develop new drugs, including targeted protein degraders, for «undruggable» proteins

Future applications for CNP - based devices include advanced drug screening, chemical and biological sensors, and increased ability to analyze cells and protein structures.

Phenotypic screening of small molecule libraries using iPSC - based models to identify novel drug candidates and disease mechanisms.

These laboratories are complemented by several additional laboratories: one that is focused on computational structure prediction and design (Phil Bradley), one that conducts solution - based protein mapping studies of large complexes involved in gene transcription (Steve Hahn) and a third that conducts drug target validation and drug screening studies (Julian Simon).

Overall, these results indicate that changes in ATP levels are a reliable indicator of cell death in stem cell populations upon drug insults and may have utility for hESC - based automatic screening assays.

These two properties (self - renewal and pluripotency) confers human pluripotent stem cells a unique interest for clinical applications since they could allow the production of infinite quantities of cells for disease modelling, drug screening and cell based therapy.

Dr. Bernard plays a critical role in the analysis of the high - throughput drug and siRNA screens as well as in drug target prioritization based on TCGA.

On March 27, 2014, the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee of the U.S. Food and Drug Administration will review the premarket approval application (PMA) for the company's Cologuard stool - DNA - based, non-invasive colorectal cancer screening test.

In addition, three California - based ALS research labs have joined forces to form the Neuro Collaborative, which will create induced pluripotent stem (iPS) cell lines from ALS patients that can be used to screen for new drugs and will be shared with the other groups.

Based on work initially funded by a Biomedical Catalyst grant from Innovate UK, the two - part Drug Screening System consists of single - use, tamper - evident Intelligent Fingerprinting Cartridges (for sample collection) and the portable Intelligent Fingerprinting Reader 1000 analysis unit.

Washington - based Costco Wholesale Corp., for example, continues to screen potential workers for drugs and conducts random employee tests on «reasonable suspicion,» according to Pat Callans, vice president of human resources at the retailer.

«This is a noteworthy distinction because it validates our commitment to providing employers with hiring peace of mind through our cloud - based suite of background screening, drug and health testing and onboarding solutions,» said Clare Hart, chief executive officer at Sterling Talent Solutions.

With our web - based screening system you can easily order and obtain applicant consent for drug testing services (along with all other employment background screening services).

Drug screening is then performed through any one of our nationwide network of facilities and results are seamlessly integrated and reported through the same web - based screening system.

HireSafe is a California based pre-employment background check company trusted since 1997 to provide job screening criminal record checks, dot drug screening, non dot drug testing and many other human resource services.

The HireRight / Incentives Advisors Partnership Through this strategic relationship, HireRight's industry - leading web - based employment background screening, drug screening, I - 9 and E-Verify services are available to Incentives Advisors» customers as a compliment to its tax credit and consulting services.

Through this strategic relationship, HireRight's industry - leading web - based employment background screening, drug screening, I - 9 and E-Verify services are delivered to Incentives Advisors» clients as part of Incentives Advisors» technology - driven, streamlined tax credit services.